drugset
drugset / Trial / NCT05293678

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

NCT05293678 ↗

Phase 1 Completed 104 enrolled Regeneron Pharmaceuticals
RandomizedSequentialQuadruple-blindTreatment

Summary

The primary objective of the study is to evaluate the safety and tolerability of REGN15160 in healthy participants, as measured by all treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (SAEs). The secondary objectives of the study are: * To assess the concentration-time profile of REGN15160 in serum * To assess the immunogenicity of REGN15160

Timeline

Start
2022-04-12
Primary completion
2023-01-26
Completion
2023-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject GORIVITUG Monoclonal antibody — Intravenous

Indications

No indication recorded.